ROCHESTER, Mich., May 02, 2018 -- OptimizeRx Corp. (OTCQB:OPRX), the nation’s leading provider of digital health messaging for the pharmaceutical industry, has entered into a definitive agreement with two institutional investors and a large family office for a private offering of common stock.
OptimizeRx will issue 5 million shares of its common stock to the investors at $1.80 per share, resulting in aggregate gross proceeds of $9 million to the company. The company intends to use the proceeds for general corporate purposes.
“Our record Q1 results demonstrate the strong momentum in our business, including growth in pharma brands, channel partners, and healthcare providers on the OptimizeRx network,” said OptimizeRx CEO, William Febbo. “We expect to use some of the proceeds from this capital raise to fund additional sales and channel investments in our core ambulatory market, where we continue to demonstrate high ROI for our pharma clients’ marketing spend. It will also support our further expansion into the hospital channel, which represents a significant growth opportunity.”
Lake Street Capital Markets is acting as the sole placement agent, with B. Riley FBR acting as an advisor to the transaction.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About OptimizeRx
OptimizeRx® (OTCQB:OPRX) is the nation’s leading provider of digital health messaging via electronic health records (EHRs), providing a direct channel for pharma companies to communicate with healthcare providers. The company’s cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, education, and critical clinical information. The company’s network is comprised of leading EHR platforms like Allscripts, Amazing Charts and Quest, and provides more than half of the ambulatory market access to these benefits within their workflow at the point of care. For more information, follow the company on Twitter, LinkedIn or visit www.optimizerx.com.
Important Cautions Regarding Forward Looking Statements
This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended and such section 21E of the Securities Act of 1934, amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
OptimizeRx Contact:
Doug Baker, CFO
Tel (248) 651-6568 x807
[email protected]
Investor Relations Contact:
Ron Both, CMA
Tel (949) 432-7557
[email protected]


Amazon to Expand Drone Delivery to 500 U.S. Locations
California Seeks Paramount Divestitures in Warner Bros. Merger
Nvidia Eyes Perplexity Investment at $30 Billion Valuation
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift
Anthropic IPO Could Challenge SpaceX’s Record $86 Billion Offering
Shein Launches $1.77 Billion Hong Kong IPO After Years of Listing Delays
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7%
Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints
SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p
Alibaba Raises $10.2 Billion to Expand AI Infrastructure
Nvidia Options Price in $280 Billion Earnings Swing 



